Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.
Neurology
Multiple sclerosis 2021 – a look ahead
January 13, 2021To start off the new year, NeuroSens asked some MS experts from across Canada what developments in multiple sclerosis research and management we can expect to see. Some issues were necessarily related to COVID-21. But the prognosticators also identified several important questions that may be answered in the months ahead.
This just in – Winners of the 2020 Awards in Multiple Sclerosis
December 16, 2020To close out the pandemic year 2020, we’ve compiled a list of proposed awards for your consideration in the field of multiple sclerosis.
McDonald 2017 update – more research required
December 9, 2020The International Panel on Diagnosis of Multiple Sclerosis is considering potential revisions to its 2017 McDonald criteria for the diagnosis of multiple sclerosis, but no formal changes are expected soon, according to Dr. Jeffrey Cohen at the ACTRIMS lecture presented at the 28th European Charcot Foundation meeting, November 25, 2020.
The Year in Review – virtual EBM and SPMS
December 2, 2020The year 2020 will be remembered for virtual visits and virtual congresses. It was also a year of the Food and Drug Administration adopting what might be termed virtual evidence-based medicine (EBM).